Sun Pharma Advanced Research Co Ltd - ESG Rating & Company Profile powered by AI
Check the bottom of this webpage for potential risks for Sun Pharma Advanced Research Co Ltd based on sector, location and marketcap. The ESG score for Sun Pharma Advanced Research Co Ltd represents the company's reporting of the United Nations SDGs. This report of Sun Pharma Advanced Research Co Ltd employs data points from across the web as well as from available disclosures by Sun Pharma Advanced Research Co Ltd.
Sun Pharma Advanced Research Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.3; made up of an environmental score of 6.0, social score of 8.0 and governance score of 4.8.
6.3
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
402 | United Laboratories International Holdings Ltd | 6.4 | High |
402 | Zenabis Global Inc | 6.4 | High |
427 | Sun Pharma Advanced Research Co Ltd | 6.3 | High |
427 | Calliditas Therapeutics AB | 6.3 | High |
427 | Carna Biosciences Inc | 6.3 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Sun Pharma Advanced Research Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Sun Pharma Advanced Research Co Ltd disclose current and historical energy intensity?
Does Sun Pharma Advanced Research Co Ltd report the average age of the workforce?
Does Sun Pharma Advanced Research Co Ltd reference operational or capital allocation in relation to climate change?
Does Sun Pharma Advanced Research Co Ltd disclose its ethnicity pay gap?
Does Sun Pharma Advanced Research Co Ltd disclose cybersecurity risks?
Does Sun Pharma Advanced Research Co Ltd offer flexible work?
Does Sun Pharma Advanced Research Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Sun Pharma Advanced Research Co Ltd disclose the number of employees in R&D functions?
Does Sun Pharma Advanced Research Co Ltd conduct supply chain audits?
Does Sun Pharma Advanced Research Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Sun Pharma Advanced Research Co Ltd conduct 360 degree staff reviews?
Does Sun Pharma Advanced Research Co Ltd disclose the individual responsible for D&I?
Does Sun Pharma Advanced Research Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Sun Pharma Advanced Research Co Ltd disclose current and / or historical scope 2 emissions?
Does Sun Pharma Advanced Research Co Ltd disclose water use targets?
Does Sun Pharma Advanced Research Co Ltd have careers partnerships with academic institutions?
Did Sun Pharma Advanced Research Co Ltd have a product recall in the last two years?
Does Sun Pharma Advanced Research Co Ltd disclose incidents of discrimination?
Does Sun Pharma Advanced Research Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Sun Pharma Advanced Research Co Ltd issued a profit warning in the past 24 months?
Does Sun Pharma Advanced Research Co Ltd disclose parental leave metrics?
Does Sun Pharma Advanced Research Co Ltd disclose climate scenario or pathway analysis?
Does Sun Pharma Advanced Research Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Sun Pharma Advanced Research Co Ltd disclose the pay ratio of women to men?
Does Sun Pharma Advanced Research Co Ltd support suppliers with sustainability related research and development?
Does Sun Pharma Advanced Research Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Sun Pharma Advanced Research Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Sun Pharma Advanced Research Co Ltd involved in embryonic stem cell research?
Does Sun Pharma Advanced Research Co Ltd disclose GHG and Air Emissions intensity?
Does Sun Pharma Advanced Research Co Ltd disclose its waste policy?
Does Sun Pharma Advanced Research Co Ltd report according to TCFD requirements?
Does Sun Pharma Advanced Research Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Sun Pharma Advanced Research Co Ltd disclose energy use targets?
Does Sun Pharma Advanced Research Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Sun Pharma Advanced Research Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Sun Pharma Advanced Research Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop an S1P receptor 1 agonist for autoimmune disorders. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited.